This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve this new drug simultaneously. We also show that a firm's best response to international reference pricing is to never launch a new drug sequentially as long as the difference in drug approval times between countries is small enough. Furthermore, we show that a firm's incentives to launch a new drug in one or another country are the same if the drug approval times are identical across countries or if the difference between approval times are small enough...
This paper investigates how regulation impinged on the launch strategies of international pharmaceut...
textabstractResearch on the launch of new products in the international realm is scarce. The present...
Research on the launch of new products in the international realm is scarce. The present paper is th...
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to...
International audienceThis paper analyzes the timing decisions of pharmaceutical firms to launch a n...
This paper analyses the impact of reimbursement regulation on launch times in the adoption of new me...
This paper models the launch decision of pharmaceutical companies in regard to new drugs and country...
BACKGROUND: New medicines are increasingly being identified as efficacious across multiple indicatio...
We analyze the effect of price regulation on delays in launch of new drugs. Because a low price in o...
This is a comparative study of the average and median approval times for pharmaceutical innovations ...
Analysis of the timing of launches of 642 new drugs in 76 countries during 1983-2002 shows that pate...
We consider how patent rights and price regulation affect whether new drugs are marketed in a countr...
This paper investigates how regulation impinged on the launch strategies of international pharmaceut...
textabstractResearch on the launch of new products in the international realm is scarce. The present...
Research on the launch of new products in the international realm is scarce. The present paper is th...
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to...
International audienceThis paper analyzes the timing decisions of pharmaceutical firms to launch a n...
This paper analyses the impact of reimbursement regulation on launch times in the adoption of new me...
This paper models the launch decision of pharmaceutical companies in regard to new drugs and country...
BACKGROUND: New medicines are increasingly being identified as efficacious across multiple indicatio...
We analyze the effect of price regulation on delays in launch of new drugs. Because a low price in o...
This is a comparative study of the average and median approval times for pharmaceutical innovations ...
Analysis of the timing of launches of 642 new drugs in 76 countries during 1983-2002 shows that pate...
We consider how patent rights and price regulation affect whether new drugs are marketed in a countr...
This paper investigates how regulation impinged on the launch strategies of international pharmaceut...
textabstractResearch on the launch of new products in the international realm is scarce. The present...
Research on the launch of new products in the international realm is scarce. The present paper is th...